Trump Healthcare Policy Changes: Reversing Biden’s Executive Orders and WHO Withdrawal

By Rene Pretorius

January 22, 2025

President Donald Trump has reversed several healthcare-related executive orders issued by Joe Biden. These include policies on COVID-19 management, artificial intelligence (AI) in healthcare, and support for the Affordable Care Act (ACA) exchanges. Trump also signed an executive order withdrawing the U.S. from the World Health Organization (WHO), citing concerns over pandemic management and political influences. We briefly review the Trump healthcare policy changes.

Drug Pricing and Healthcare Costs

Trump rescinded an executive order requiring the Center for Medicare and Medicaid Innovation (CMMI) to test models aimed at controlling drug spending. This decision halted experiments on high-value drugs and outcome-based payment agreements. His administration also abandoned Biden’s initiatives to cap insulin costs and allow Medicare to negotiate drug prices.

Both administrations addressed drug pricing differently. Trump proposed a “most favored nation pricing” model to align Medicare drug costs with those in other high-income countries. Biden later rescinded this policy and introduced measures through the Inflation Reduction Act to control prescription costs.

Impact on Global Health and U.S. Policy

The U.S. has been a key WHO member and top donor, contributing $1.28 billion in 2022 and 2023. Trump’s withdrawal order claims the WHO’s pandemic response and financial structures are unfair. This move may weaken global health initiatives and limit U.S. influence in international health policies.

Reversing COVID-19 response directives could disrupt federal coordination in future pandemics. Changes in AI regulations might slow the adoption of new healthcare technologies, affecting efficiency and patient outcomes. These policy shifts highlight the ongoing debate between Trump’s and Biden’s healthcare strategies.

Consequences for Stakeholders

Trump’s changes impact healthcare providers, insurers, and pharmaceutical companies. Uncertainty in drug pricing regulations and global health engagement may alter strategic planning. Medicare recipients could face higher prescription costs. The policy shifts signal a fundamental realignment of healthcare priorities, affecting multiple sectors of the industry.

 

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.